| Description |
CGP 35348 is a selective, brain penetrant, centrally active GABAB receptor antagonist with an EC50 of 34 μM. CGP 35348 shows affinity for the GABAB receptor only[1]. CGP 35348 has a potential to improve neuromuscular coordination and spatial learning in albino mouse following neonatal brain damage[2].
|
| Related Catalog |
|
| In Vivo |
CGP 35348 enhances non-REM sleep and rapid eye movement (REM) sleep and reduces strongly spike-wave discharges. Both behavioural and electroencephalogram (EEG) parameters contributed to the establishment of a hypnotic effect. The highest dose of CGP 35348 was not effective in promoting REM sleep. The REM-sleep-enhancing effects might have theoretical and clinical relevance. Animal Model: Eight male Wistar rats[3] Dosage: 100, 300, and 900 mg/kg Administration: Intraperitoneally given Result: Produced an increase in the duration of REM sleep compared to the saline-injected control group at 100 and 300 mg/kg.
|
| References |
[1]. H R Olpe,et al. CGP 35348: a centrally active blocker of GABAB receptors. CGP 35348: a centrally active blocker of GABAB receptors [2]. Q Gillani, et al. CGP 35348, GABA B receptor antagonist, has a potential to improve neuromuscular coordination and spatial learning in albino mouse following neonatal brain damage. Biomed Res Int. 2014;2014:295215. [3]. A Puigcerver, et al. Effects of the GABAB antagonist CGP 35348 on sleep-wake states, behaviour, and spike-wave discharges in old rats. Brain Res Bull. 1996;40(3):157-62.
|
